Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 15, Issue 3, 2013, Pages 323-327

  Oshima, K ^a,b   Kanda, Y ^a,b   Kako, S ^a,b   Ohno, K ^c   Kishino, S ^c   Kurokawa, M ^b,d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

HSCT; Liver function; Micafungin; Pharmacokinetics

Indexed keywords

BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; MICAFUNGIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; LIVER DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT DURATION;

ADULT; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIPOPEPTIDES; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MYCOSES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84878635950     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12070     Document Type: Article

References (13)

1. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71 (1): 11-41.
2. Carver PL. Micafungin. Ann Pharmacother 2004; 38 (10): 1707-1721.
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362 (9390): 1142-1151.
4. Yanni SB, Augustijns PF, Benjamin DK Jr, Brouwer KL, Thakker DR, Annaert PP. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos 2010; 38 (10): 1848-1856.
5. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36 (5): 372-379.
6. Hashino S, Morita L, Takahata M, et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 2008; 87 (1): 91-97.
7. Azuma J, Nakahara K, Kagayama A, et al. Phase I study of micafungin. Jpn J Chemother 2002; 50 (Suppl 1): 104-147.
8. Kishino S, Ohno K, Shimamura T, Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004; 18 (6): 676-680.
9. Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet 2006; 21 (4): 324-331.
10. Nakagawa Y, Ichii Y, Saeki Y, Kodaka M, Suzuki K, Kishino S. Plasma concentration of micafungin in patients with hematologic malignancies. J Infect Chemother 2007; 13 (1): 39-45.
11. Nakagawa Y, Ichii Y, Saeki Y, Kodama M, Kishino S, Suzuki K. Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies. Eur J Drug Metab Pharmacokinet 2008; 33 (3): 191-198.
12. Shimoeda S, Ohta S, Kobayashi H, et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 2005; 28 (3): 477-480.
13. Shimoeda S, Ohta S, Kobayashi H, Yamato S, Sasaki M, Kawano K. Effective blood concentration of micafungin for pulmonary aspergillosis. Biol Pharm Bull 2006; 29 (9): 1886-1891.